Recordati Industria Chimica E Farmaceutica S.P.A. (OTCMKTS:RCDTF – Get Free Report) was the recipient of a significant drop in short interest during the month of June. As of June 30th, there was short interest totaling 191,938 shares, a drop of 35.0% from the June 15th total of 295,188 shares. Based on an average daily volume of 20 shares, the days-to-cover ratio is currently 9,596.9 days. Approximately 0.1% of the shares of the company are short sold.
Recordati Industria Chimica E Farmaceutica Stock Performance
Shares of RCDTF stock opened at $58.00 on Friday. The company has a market cap of $11.97 billion, a P/E ratio of 21.94 and a beta of 0.25. Recordati Industria Chimica E Farmaceutica has a 52 week low of $55.88 and a 52 week high of $60.00. The company has a quick ratio of 0.86, a current ratio of 1.26 and a debt-to-equity ratio of 0.85. The business has a 50 day moving average of $58.29 and a two-hundred day moving average of $59.88.
Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF – Get Free Report) last posted its quarterly earnings data on Wednesday, May 13th. The company reported $1.08 earnings per share for the quarter. The business had revenue of $834.86 million during the quarter. Recordati Industria Chimica E Farmaceutica had a net margin of 17.81% and a return on equity of 34.38%.
About Recordati Industria Chimica E Farmaceutica
Recordati Industria Chimica e Farmaceutica is an Italy‐based international pharmaceutical company engaged in the research, development, manufacturing and commercialization of therapeutic products. Established in 1926, the company has built a diversified portfolio that includes proprietary drugs, generics and orphan medicines, with a particular emphasis on treatments for rare diseases. Recordati’s product range spans cardiovascular, urology, endocrinology, dermatology and oncology therapies, as well as specialized formulations for genetic and metabolic disorders.
The company’s historical roots date back nearly a century, when it began as a family‐owned enterprise in Milan.
See Also
- Five stocks we like better than Recordati Industria Chimica E Farmaceutica
- Has Broadcom Become Too Expensive for Its AI Story?
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
Receive News & Ratings for Recordati Industria Chimica E Farmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recordati Industria Chimica E Farmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
